Long-Term Therapy With Bevacizumab in a Patient With Glanzmann’s Thrombasthenia and Recurrent Digestive Bleeding due to Gastrointestinal Angiodysplastic Lesions
Authors:
- 1 February 2015
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 110 (2) , 352-353
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Management of Gastrointestinal Angiodysplastic Lesions (GIADs): A Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology, 2014
- Bevacizumab as Rescue Treatment for Severe Recurrent Gastrointestinal Bleeding in Hereditary Hemorrhagic TelangiectasiaJournal of Clinical Gastroenterology, 2013
- Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac OutputJAMA, 2012
- Long-Term Therapy with Bevacizumab in Hereditary Hemorrhagic TelangiectasiaNew England Journal of Medicine, 2011
- Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case seriesEuropean Journal of Gastroenterology & Hepatology, 2009
- A Pilot Study of Thalidomide in Recurrent GI Bleeding Due to AngiodysplasiasDigestive Diseases and Sciences, 2007
- Thalidomide sensory neurotoxicityNeurology, 2004
- Long‐lasting intestinal bleeding in an old patient with multiple mucosal vascular abnormalities and Glanzmann's thrombasthenia: 3‐year pharmacological managementJournal of Internal Medicine, 2002